Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 240 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dementia Moderate Clear all
Completed Phase 3 Interventional Results available

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor

NCT02006654
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
26
States / cities
Mesa, Arizona • Bellflower, California • Costa Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Phase 3 Interventional

ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)

NCT00231946
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VP4896
Drug
Lead sponsor
Voyager Pharmaceutical Corporation
Industry
Eligibility
60 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
55
States / cities
Peoria, Arizona • Tucson, Arizona • Fresno, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Jul 22, 2026, 2:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

NCT05834296
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo
Biological · Drug
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Doral, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

ELND005 in Patients With Mild to Moderate Alzheimer's Disease

NCT00568776
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo Control, ELND005
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
50
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Not applicable Interventional

Effect of NeuroAD on the Cognitive Function of Alzheimer Patients

NCT01825330
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TMS and cognitive stimulation, sham
Device
Lead sponsor
Neuronix Ltd
Industry
Eligibility
60 Years to 90 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Sun City, Arizona • Costa Mesa, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Jul 22, 2026, 2:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

NCT04639050
View directory record Official record
Conditions
Alzheimers Disease
Interventions
RO7126209, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
17
States / cities
Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Phase 2 Interventional

Curcumin in Patients With Mild to Moderate Alzheimer's Disease

NCT00099710
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Curcumin C3 Complex
Dietary Supplement
Lead sponsor
John Douglas French Foundation
Other
Eligibility
50 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Phase 3 Interventional

18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

NCT00103649
View directory record Official record
Conditions
Alzheimer Disease
Interventions
xaliproden (SR57746A)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2008 · Synced Jul 22, 2026, 2:23 PM EDT
Terminated Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

NCT02220738
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-957, Placebo for ABT-957
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Glendale, California • Orlando, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Jul 22, 2026, 2:23 PM EDT
Not listed Phase 2 Interventional

Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease

NCT00174525
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AAB-001
Drug
Lead sponsor
Pharmacology Research Institute
Other
Eligibility
50 Years to 85 Years
Timeline
2005 – 2008
U.S. locations
2
States / cities
Los Alamitos, California • Northridge, California
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease

NCT00381238
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Sun City, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD

NCT05004688
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Dementia, Moderate Dementia, Alzheimer Disease
Interventions
Biological/Vaccine: Bacillus Calmette-Guerin (BCG)
Biological
Lead sponsor
Steven E Arnold, MD
Other
Eligibility
55 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease

NCT00481520
View directory record Official record
Conditions
Alzheimer Disease
Interventions
SAM-531, placebo
Drug · Other
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
50 Years to 90 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Delray Beach, Florida • Hallandale, Florida • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2009 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease

NCT02560753
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
T3D-959
Drug
Lead sponsor
T3D Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Delray Beach, Florida • Miami, Florida • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Jul 22, 2026, 2:23 PM EDT
Not listed Phase 3 Interventional

Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease

NCT00314912
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Tramiprosate (3APS)
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
50 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2007 · Synced Jul 22, 2026, 2:23 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

NCT06881836
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ONO-2020, Placebo
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
55 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
76
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study for Safety and Tolerability of AL002.

NCT03635047
View directory record Official record
Conditions
Healthy, Alzheimer Disease
Interventions
AL002, Saline Solution
Biological · Other
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Not applicable Interventional

Neurostimulation for Cognitive Enhancement in Alzheimer's Disease

NCT04404153
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS., tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.
Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 22, 2026, 2:23 PM EDT
Withdrawn Phase 2 Interventional

Dronabinol for Agitation in Dementia Crossover Trial

NCT05612711
View directory record Official record
Conditions
Dementia Moderate, Dementia Severe, Agitation,Psychomotor, Behavioral Symptoms
Interventions
Dronabinol
Drug
Lead sponsor
Ralph H. Johnson VA Medical Center
Federal
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

NCT03625622
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
AR1001, Placebo
Drug
Lead sponsor
AriBio Co., Ltd.
Industry
Eligibility
55 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
21
States / cities
Banning, California • Sacramento, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jul 22, 2026, 2:23 PM EDT
Not listed Phase 4 Interventional

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCT06093451
View directory record Official record
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Phase 1 Interventional Results available

A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease

NCT00988598
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Glendale, California • Gainesville, Florida • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Phase 3 Interventional

To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.

NCT00151502
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Atorvastatin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
40
States / cities
Sun City, Arizona • Fresno, California • Laguna Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 22, 2026, 2:23 PM EDT
Completed Not applicable Interventional

Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease

NCT00467766
View directory record Official record
Conditions
Alzheimer Disease, Caregivers
Interventions
Psychosocial information, counseling, and support, Donepezil (Aricept)
Behavioral · Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2007 · Synced Jul 22, 2026, 2:23 PM EDT